{"nctId":"NCT00162942","briefTitle":"Study for the Treatment of Crohn's Disease With Adacolumn","startDateStruct":{"date":"2005-01"},"conditions":["Crohn's Disease"],"count":235,"armGroups":[{"label":"Adacolumn","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Adacolumn"]},{"label":"Sham","type":"SHAM_COMPARATOR","interventionNames":["Device: Sham"]}],"interventions":[{"name":"Adacolumn","otherNames":[]},{"name":"Sham","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Moderate to severe Crohn's disease\n* Adequate peripheral venous access\n* Agree to participate in the required follow-up visits\n* Able to complete a diary\n* Signed written informed consent document and authorization for use of protected health information\n\nKey Exclusion Criteria:\n\n* Extremely severe Crohn's disease\n* Known obstructive symptoms within the past 3 months\n* Presence of toxic megacolon\n* Major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks\n* Total colectomy, ileostomy, stoma or 100 cm of resected small bowel\n* Requiring in-patient hospitalization\n* A history of allergic reaction to heparin or heparin-induced thrombocytopenia\n* A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures\n* A history of severe cardiovascular or peripheral arterial diseases\n* A history of cerebral vascular diseases\n* Liver diseases\n* Renal insufficiency\n* Known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment\n* Any hypercoagulable disorder\n* Known infection with Hepatitis B or C, or HIV\n* Severe anemia\n* Leukopenia or granulocytopenia\n* Evidence of current systemic infection\n* Malignancy\n* Pregnant, lactating or planning to become pregnant during the course of the investigational study\n* Used within the last 30 days, an investigational drug, biologic or device or 5 half-lives, if known, for any investigational drug or biologic","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Remission","description":"Clinical Remission is defined as a Crohn's Disease Activity Index (CDAI) score of ≤150 when evaluated at Week 12","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Frequency and Severity of Adverse Events Through Week 12","description":"All subjects who received at least one apheresis treatment session were included in the intent-to-treat population (ITT). The ITT population was used for effectiveness analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.1","spread":null},{"groupId":"OG001","value":"75.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"CDAI Score Change From Baseline","description":"601-point, ordinal scale which quantifies the symptoms of patients with Crohn's Disease from 0 (complete remission) to 600 (most severe active disease). Mean change=Week 12 Mean CDAI-Baseline Mean CDAI","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-65.6","spread":"96.6"},{"groupId":"OG001","value":"-62.3","spread":"103"}]}]}]},{"type":"SECONDARY","title":"Clinical Response","description":"Clinical Response is defined as a ≥ 100-point reduction in the CDAI scores at Week 12","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"26.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Short-Form 36 Questionnaire (SF-36) Physical Component Summary (PCS) Score","description":"101-point, ordinal scale measuring general health of patients from 0 (low quality of life) to 100 (high quality of life), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.84","spread":"8.76"},{"groupId":"OG001","value":"3.29","spread":"9.19"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Short-Form 36 Questionnaire (SF-36) Mental Component Summary (MCS) Score","description":"101-point, ordinal scale measuring general health of patients from 0 (low quality of life) to 100 (high quality of life), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"10.13"},{"groupId":"OG001","value":"2.48","spread":"11.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Inflammatory Bowel Diseases Questionnaire (IBDQ)","description":"193-point, ordinal scale measuring disease-specific quality of life from 32 (low quality of life) to 224 (high quality of life). Mean change= Week 12 Mean-Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"32.1"},{"groupId":"OG001","value":"16.8","spread":"37.9"}]}]}]},{"type":"SECONDARY","title":"Mean Change in EuroQol Score (Single Index)","description":"A continuous scale that is a cardinal index of health from 0 (no impairment) to 1 (most impairment), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0392","spread":"0.2239"},{"groupId":"OG001","value":"0.0917","spread":"0.2648"}]}]}]},{"type":"SECONDARY","title":"Mean Change in EuroQol Score (Visual Analog Scale)","description":"101-point, ordinal scale which measures non-disease specific health-related quality of life from 0 (Worst imaginable health state) to 100 (best imaginable health state)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"19.8"},{"groupId":"OG001","value":"5.5","spread":"18.6"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Work Limitations Questionnaire (Time Management)","description":"101-point, ordinal scale which measures the degree to which health problems interfere with certain aspects of job performance and productivity from 0 (limited none of the time) to 100 (limited all the time), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":"25.5"},{"groupId":"OG001","value":"-6.6","spread":"31.7"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Work Limitations Questionnaire (Physical Demands)","description":"101-point, ordinal scale which measures the degree to which health problems interfere with certain aspects of job performance and productivity from 0 (limited none of the time) to 100 (limited all the time), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"23.1"},{"groupId":"OG001","value":"2.3","spread":"22.7"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Work Limitations Questionnaire (Mental-Interpersonal Demands)","description":"101-point, ordinal scale which measures the degree to which health problems interfere with certain aspects of job performance and productivity from 0 (limited none of the time) to 100 (limited all the time), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"20.5"},{"groupId":"OG001","value":"-2.7","spread":"20.8"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Work Limitations Questionnaire (Output Demands)","description":"101-point, ordinal scale which measures the degree to which health problems interfere with certain aspects of job performance and productivity from 0 (limited none of the time) to 100 (limited all the time), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"25.8"},{"groupId":"OG001","value":"-3.8","spread":"28.7"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Work Limitations Questionnaire (WLQ Index)","description":"101-point, ordinal scale which measures the degree to which health problems interfere with certain aspects of job performance and productivity from 0 (limited none of the time) to 100 (limited all the time), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"5.6"},{"groupId":"OG001","value":"-0.5","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Crohn's Disease Endoscopic Index of Severity","description":"26-point,ordinal scale that assesses the severity of Crohn's Disease from 0 (least severe) to 26 (most severe), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"7.73"},{"groupId":"OG001","value":"-4.63","spread":"13.20"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Subject Global Rating","description":"7-point,ordinal scale that measures the subject's state of Crohn's Disease from 0 (totally inactive) to 7 (as bad as it gets), Mean change=Week 12 Mean -Baseline Mean","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.6"},{"groupId":"OG001","value":"-0.6","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Mean Change in C-Reactive Protein","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":"22.67"},{"groupId":"OG001","value":"0.24","spread":"12.59"}]}]}]},{"type":"POST_HOC","title":"Clinical Response in Subjects With a CDAI Score Greater Than 300","description":"A clinical response is defined as a 70-point decrease in CDAI score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]}]},{"type":"POST_HOC","title":"Clinical Response in Subjects With a CDAI Score Less Than or Equal to 300","description":"A clinical response is defined as a 70-point decrease in CDAI score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"43.3","spread":null}]}]}]},{"type":"POST_HOC","title":"Clinical Response Based on Previous Use of Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors","description":"A clinical response is defined as a 70-point decrease in CDAI score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"21.1","spread":null}]}]}]},{"type":"POST_HOC","title":"Clinical Response Based on No Previous Use of Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors","description":"A clinical response is defined as a 70-point decrease in CDAI score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.5","spread":null},{"groupId":"OG001","value":"37.3","spread":null}]}]}]},{"type":"POST_HOC","title":"Clinical Response Based on Use of 5-Aminosylisalates During the Study","description":"A clinical response is defined as a 70-point decrease in CDAI score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null},{"groupId":"OG001","value":"21.7","spread":null}]}]}]},{"type":"POST_HOC","title":"Clinical Response Based on no Use of 5-Aminosylisalates During the Study","description":"A clinical response is defined as a 70-point decrease in CDAI score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":null},{"groupId":"OG001","value":"38.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}